What predicts attrition in second step medication treatments for depression?: a STAR*D Report.

TitleWhat predicts attrition in second step medication treatments for depression?: a STAR*D Report.
Publication TypeJournal Article
Year of Publication2009
AuthorsWarden, D, Rush JA, Wisniewski SR, Lesser IM, Kornstein SG, Balasubramani GK, Thase ME, Preskorn SH, Nierenberg AA, Young EA, Shores-Wilson K, Trivedi MH
JournalThe international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP)
Volume12
Issue4
Pagination459-73
Date Published2009 May
ISSN1469-5111
KeywordsAdolescent, Adult, Aged, Antidepressive Agents, Antidepressive Agents, Second-Generation, Bupropion, Buspirone, Citalopram, Data Interpretation, Statistical, Depressive Disorder, Major, Drug Therapy, Combination, Female, Forecasting, Humans, Male, Middle Aged, Outpatients, Patient Dropouts, Prospective Studies, Psychiatric Status Rating Scales, Quality of Life, Serotonin Receptor Agonists, Socioeconomic Factors, Young Adult
Abstract

Attrition rates are high during treatment for major depressive disorder (MDD), and patients who drop out are less likely to reach remission. This report evaluates the incidence, timing, and predictors of attrition during second-step medication treatment. Outpatients in the multisite Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study receiving a medication augmentation (n=563) or medication switch (n=723) for non-psychotic MDD after an unsatisfactory outcome with citalopram were evaluated to determine attrition rates and pretreatment sociodemographic or clinical predictors of attrition. Twenty percent of participants receiving a medication augmentation and 27% receiving a medication switch dropped out before 12 wk in the second treatment step. Remission rates were lower for dropouts [7% vs. 43% (medication augmentation); 12% vs. 31% (medication switch)]. For medication augmentation, Black and other non-Caucasian races, Hispanic ethnicity, younger age, family history of drug abuse, concurrent drug abuse, sociodemographic disadvantage, less symptom improvement with initial citalopram treatment, and greater symptom severity when beginning augmentation were associated with attrition. For medication switch, Black and other non-Caucasian races, younger age, more melancholic features, and lower exit doses but more severe side-effects with citalopram treatment were associated with attrition. Minority status, younger age, and greater difficulty with the first treatment step are risk factors for attrition in the second treatment step. Focus on patients with attrition risk factors for medication augmentation or switch strategies may enhance retention and improve outcomes.

DOI10.1111/j.1530-0277.2011.01591.x
Alternate JournalInt. J. Neuropsychopharmacol.